Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neurofibromatosis 1 4Melanoma 4Pancreatic Neoplasms 3Neurofibroma, Plexiform 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Rectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thymoma 1Small Cell Lung Carcinoma 1Sarcoma 1Peripheral Nervous System Diseases 1Pain 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Heredodegenerative Disorders, Nervous System 1

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cystadenocarcinoma, Serous × AZD 6244 × Clear all
NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡